With the development of tumor behaviors and immunological molecular mechanisms, immunotherapy provides a novel site for tumor targeting therapy, especially immune checkpoint inhibitors (ICIs) (65–67), including CTLA4, PD-1, and PD-L1. Here, CTLA4 is linked to neoplasm.